The objective of this study was to determine the clinical significance of P62c-myc protein expression in breast cancer. P62c-myc protein was detected in 107 patients with breast cancer by immunohistochemical techniques (LSAB). The results showed that the positive rate of P62c-myc protein expression was 63.55% (68/107). The overexpression of P62c-myc protein related negatively with survival. 94.00% of the cases with overexpression of P62c-myc protein survived < or = 5 years, 65.00% survived > 5 years-< 10 years, and 21.62% survived > or = 10 years. There were significant associations of P62c-myc expression with advance clinical stage, high histological grade, and positive axillary node status in breast cancers. All of these findings suggested that overexpression of P62c-myc might be an important prognostic factor, and the detection of P62c-myc protein might be arranged as a regular pathological examination in the cases of breast cancer.